RU2012122180A - Способы диагностики синдрома раздраженного кишечника - Google Patents
Способы диагностики синдрома раздраженного кишечника Download PDFInfo
- Publication number
- RU2012122180A RU2012122180A RU2012122180/15A RU2012122180A RU2012122180A RU 2012122180 A RU2012122180 A RU 2012122180A RU 2012122180/15 A RU2012122180/15 A RU 2012122180/15A RU 2012122180 A RU2012122180 A RU 2012122180A RU 2012122180 A RU2012122180 A RU 2012122180A
- Authority
- RU
- Russia
- Prior art keywords
- ibs
- sample
- level
- marker
- concentration
- Prior art date
Links
- 238000002405 diagnostic procedure Methods 0.000 title 1
- 230000000968 intestinal effect Effects 0.000 title 1
- 208000011580 syndromic disease Diseases 0.000 title 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims abstract 76
- 239000003550 marker Substances 0.000 claims abstract 42
- 238000000034 method Methods 0.000 claims abstract 39
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims abstract 29
- 229940076279 serotonin Drugs 0.000 claims abstract 12
- 102000010909 Monoamine Oxidase Human genes 0.000 claims abstract 10
- 108010062431 Monoamine oxidase Proteins 0.000 claims abstract 10
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims abstract 10
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 claims abstract 8
- 210000004369 blood Anatomy 0.000 claims abstract 8
- 239000008280 blood Substances 0.000 claims abstract 8
- 210000002966 serum Anatomy 0.000 claims abstract 8
- 108010025020 Nerve Growth Factor Proteins 0.000 claims abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 6
- -1 5-HT glucuronide Chemical class 0.000 claims abstract 5
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 claims abstract 5
- 102100021752 Corticoliberin Human genes 0.000 claims abstract 5
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 claims abstract 5
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims abstract 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims abstract 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract 5
- 101800002372 Motilin Proteins 0.000 claims abstract 5
- 102400001357 Motilin Human genes 0.000 claims abstract 5
- 101800000399 Neurokinin A Proteins 0.000 claims abstract 5
- 102400000097 Neurokinin A Human genes 0.000 claims abstract 5
- HEAUFJZALFKPBA-YRVBCFNBSA-N Neurokinin A Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)O)C1=CC=CC=C1 HEAUFJZALFKPBA-YRVBCFNBSA-N 0.000 claims abstract 5
- NHXYSAFTNPANFK-HDMCBQFHSA-N Neurokinin B Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC(O)=O)C1=CC=CC=C1 NHXYSAFTNPANFK-HDMCBQFHSA-N 0.000 claims abstract 5
- 102000046798 Neurokinin B Human genes 0.000 claims abstract 5
- 101800002813 Neurokinin-B Proteins 0.000 claims abstract 5
- 108010059705 Urocortins Proteins 0.000 claims abstract 5
- 102000005630 Urocortins Human genes 0.000 claims abstract 5
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 claims abstract 5
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 claims abstract 5
- 108060000200 adenylate cyclase Proteins 0.000 claims abstract 5
- 102000030621 adenylate cyclase Human genes 0.000 claims abstract 5
- 108700022763 carbohydrate-deficient transferrin Proteins 0.000 claims abstract 5
- 229940041967 corticotropin-releasing hormone Drugs 0.000 claims abstract 5
- KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 claims abstract 5
- 229930182480 glucuronide Natural products 0.000 claims abstract 5
- 229940088597 hormone Drugs 0.000 claims abstract 5
- 239000005556 hormone Substances 0.000 claims abstract 5
- 229960000890 hydrocortisone Drugs 0.000 claims abstract 5
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 claims abstract 5
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 claims abstract 5
- 229940053128 nerve growth factor Drugs 0.000 claims abstract 5
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims abstract 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract 5
- 239000000777 urocortin Substances 0.000 claims abstract 5
- RVWZUOPFHTYIEO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Natural products C1=C(O)C=C2C(C(=O)O)=CNC2=C1 RVWZUOPFHTYIEO-UHFFFAOYSA-N 0.000 claims abstract 4
- 239000003310 5-hydroxyindoleacetic acid Substances 0.000 claims abstract 4
- 108010078791 Carrier Proteins Proteins 0.000 claims abstract 4
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 claims abstract 4
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 claims abstract 4
- 101000830742 Homo sapiens Tryptophan 5-hydroxylase 1 Proteins 0.000 claims abstract 4
- 102100024971 Tryptophan 5-hydroxylase 1 Human genes 0.000 claims abstract 4
- 102100040198 UDP-glucuronosyltransferase 1-6 Human genes 0.000 claims abstract 4
- 101710008381 UGT1A6 Proteins 0.000 claims abstract 4
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 claims abstract 4
- 238000003745 diagnosis Methods 0.000 claims abstract 2
- 230000000697 serotonin reuptake Effects 0.000 claims abstract 2
- 239000000523 sample Substances 0.000 claims 37
- 208000024891 symptom Diseases 0.000 claims 13
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 8
- 108700039882 Protein Glutamine gamma Glutamyltransferase 2 Proteins 0.000 claims 8
- 102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 claims 8
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 claims 7
- 108050006599 Metalloproteinase inhibitor 1 Proteins 0.000 claims 7
- 239000000090 biomarker Substances 0.000 claims 7
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 claims 4
- 101001027327 Bos taurus Growth-regulated protein homolog alpha Proteins 0.000 claims 4
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 4
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 4
- 102000016950 Chemokine CXCL1 Human genes 0.000 claims 4
- 102000013382 Gelatinases Human genes 0.000 claims 4
- 108010026132 Gelatinases Proteins 0.000 claims 4
- 102000003777 Interleukin-1 beta Human genes 0.000 claims 4
- 108090000193 Interleukin-1 beta Proteins 0.000 claims 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 4
- 102000019298 Lipocalin Human genes 0.000 claims 4
- 108050006654 Lipocalin Proteins 0.000 claims 4
- 102000013519 Lipocalin-2 Human genes 0.000 claims 4
- 108010051335 Lipocalin-2 Proteins 0.000 claims 4
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims 4
- 102000001400 Tryptase Human genes 0.000 claims 4
- 108060005989 Tryptase Proteins 0.000 claims 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 4
- JFWYSGGSCOOBGK-UHFFFAOYSA-N [3-(2-azaniumylethyl)-1h-indol-5-yl] sulfate Chemical compound C1=C(OS(O)(=O)=O)C=C2C(CCN)=CNC2=C1 JFWYSGGSCOOBGK-UHFFFAOYSA-N 0.000 claims 4
- 230000006907 apoptotic process Effects 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 4
- 210000004556 brain Anatomy 0.000 claims 4
- 230000001086 cytosolic effect Effects 0.000 claims 4
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims 4
- 229960001340 histamine Drugs 0.000 claims 4
- 239000000411 inducer Substances 0.000 claims 4
- 210000000440 neutrophil Anatomy 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 229940081969 saccharomyces cerevisiae Drugs 0.000 claims 4
- 238000007619 statistical method Methods 0.000 claims 4
- 210000004877 mucosa Anatomy 0.000 claims 3
- 230000000508 neurotrophic effect Effects 0.000 claims 3
- 238000002965 ELISA Methods 0.000 claims 2
- 101000651298 Homo sapiens TRAF-interacting protein with FHA domain-containing protein A Proteins 0.000 claims 2
- 102100027651 TRAF-interacting protein with FHA domain-containing protein A Human genes 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 206010010774 Constipation Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 1
- 102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 claims 1
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 230000000931 anti-neutrophil effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 239000003900 neurotrophic factor Substances 0.000 claims 1
- 102100023995 Beta-nerve growth factor Human genes 0.000 abstract 1
- SNIXRMIHFOIVBB-UHFFFAOYSA-N N-Hydroxyl-tryptamine Chemical compound C1=CC=C2C(CCNO)=CNC2=C1 SNIXRMIHFOIVBB-UHFFFAOYSA-N 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
- 102000023732 binding proteins Human genes 0.000 abstract 1
- 108091008324 binding proteins Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25671709P | 2009-10-30 | 2009-10-30 | |
| US61/256,717 | 2009-10-30 | ||
| US26458809P | 2009-11-25 | 2009-11-25 | |
| US61/264,588 | 2009-11-25 | ||
| US32617610P | 2010-04-20 | 2010-04-20 | |
| US61/326,176 | 2010-04-20 | ||
| PCT/US2010/054810 WO2011053831A1 (en) | 2009-10-30 | 2010-10-29 | Methods for diagnosing irritable bowel syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012122180A true RU2012122180A (ru) | 2013-12-10 |
Family
ID=43922588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012122180/15A RU2012122180A (ru) | 2009-10-30 | 2010-10-29 | Способы диагностики синдрома раздраженного кишечника |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20120315630A1 (enExample) |
| EP (1) | EP2494074A4 (enExample) |
| JP (1) | JP2013509593A (enExample) |
| KR (1) | KR20120101038A (enExample) |
| CN (1) | CN102712956A (enExample) |
| AU (1) | AU2010313292A1 (enExample) |
| BR (1) | BR112012010108A2 (enExample) |
| CA (1) | CA2778539A1 (enExample) |
| IL (1) | IL219317A0 (enExample) |
| MX (1) | MX2012005015A (enExample) |
| PH (1) | PH12012500850A1 (enExample) |
| RU (1) | RU2012122180A (enExample) |
| WO (1) | WO2011053831A1 (enExample) |
| ZA (1) | ZA201203718B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5857503B2 (ja) * | 2010-07-29 | 2016-02-10 | 小野薬品工業株式会社 | ストレス性疾患のバイオマーカー |
| WO2012158831A1 (en) | 2011-05-16 | 2012-11-22 | Prometheus Laboratories Inc. | Performance of a biomarker panel for irritable bowel syndrome |
| NZ702643A (en) * | 2012-05-19 | 2016-06-24 | Falk Pharma Gmbh | Compositions and methods for treatment of irritable bowel syndrome with 5-aminosalicylate |
| AU2013326133B2 (en) * | 2012-10-05 | 2019-07-04 | Société des Produits Nestlé S.A. | Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for IBS |
| WO2014082034A1 (en) * | 2012-11-26 | 2014-05-30 | Lexicon Pharmaceuticals, Inc. | Methods for treating irritable bowel syndrome |
| CN103175971B (zh) * | 2013-02-28 | 2016-10-05 | 苏州和锐医药科技有限公司 | 一种IgA抗体检测试剂盒 |
| EP3800470A1 (en) * | 2013-03-15 | 2021-04-07 | Sera Prognostics, Inc. | Biomarkers and methods for predicting preterm birth |
| GB201305708D0 (en) * | 2013-03-28 | 2013-05-15 | Clasado Inc | Novel use |
| RU2015155552A (ru) * | 2013-05-24 | 2017-06-27 | Нестек С.А. | Путеспецифические способы прогнозирования диагноза синдрома раздраженного кишечника |
| CA2930330A1 (en) * | 2013-12-27 | 2015-07-02 | Dignity Health | Diagnosing and treating alzheimer's disease |
| JP6713723B2 (ja) * | 2014-02-18 | 2020-06-24 | 小野薬品工業株式会社 | 過敏性腸症候群の診断用バイオマーカー |
| US10392665B2 (en) | 2015-06-19 | 2019-08-27 | Sera Prognostics, Inc. | Biomarker pairs for predicting preterm birth |
| CN106446599A (zh) * | 2015-08-11 | 2017-02-22 | 中国科学院青岛生物能源与过程研究所 | 一种筛选婴幼儿龋病的口腔致病性生物标记物的方法 |
| CN105687225B (zh) * | 2016-02-26 | 2018-07-06 | 四川好医生攀西药业有限责任公司 | 一种治疗肠易激综合征的药物组合物及其制备方法和应用 |
| GB201605110D0 (en) * | 2016-03-24 | 2016-05-11 | Mologic Ltd | Detecting sepsis |
| US10817778B2 (en) | 2016-06-27 | 2020-10-27 | International Business Machines Corporation | Customized cooking utilizing deep learning neuromorphic computing of hyperspectral input |
| AU2017325986B2 (en) * | 2016-09-16 | 2023-12-14 | Takeda Pharmaceutical Company Limited | Metabolite biomarkers for diseases associated with the contact activation system |
| RU2668496C2 (ru) * | 2017-03-16 | 2018-10-01 | Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр Департамента здравоохранения города Москвы | Способ диагностики тяжести течения синдрома раздраженного кишечника |
| CN106990057A (zh) * | 2017-05-05 | 2017-07-28 | 贵州普洛迈德生物工程有限公司 | 一种检测5‑羟吲哚乙酸试剂及制备方法 |
| US11662351B2 (en) | 2017-08-18 | 2023-05-30 | Sera Prognostics, Inc. | Pregnancy clock proteins for predicting due date and time to birth |
| US11488699B1 (en) | 2018-12-09 | 2022-11-01 | Cerner Innovation, Inc. | Microbiota activity sensor and decision support tool |
| US11842795B1 (en) * | 2018-12-17 | 2023-12-12 | Cerner Innovation, Inc. | Irritable bowel syndrome diagnostic sensor and decision support tool |
| KR102330639B1 (ko) * | 2019-01-18 | 2021-11-24 | 주식회사 천랩 | 과민성대장증후군 특이적 미생물 바이오마커와 이를 이용하여 과민성대장증후군의 위험도를 예측하는 방법 |
| US20220146527A1 (en) * | 2019-09-17 | 2022-05-12 | Chang Gung University | Method of creating characteristic profiles of mass spectra and identification model for analyzing and identifying features of microorganisms |
| US20240124524A1 (en) * | 2019-10-17 | 2024-04-18 | University Of Copenhagen | Agonist of Tacr2 |
| CN112921100A (zh) * | 2019-12-06 | 2021-06-08 | 宁波海尔施基因科技有限公司 | 一种检测人类压力敏感度基因型的试剂盒和方法 |
| EP3913371A1 (en) * | 2020-05-18 | 2021-11-24 | Neuroimmun GmbH | Method and kit for diagnosting irritable bowel syndrome and for its relief through dietary interventions |
| CN111784683B (zh) * | 2020-07-10 | 2022-05-17 | 天津大学 | 病理切片检测方法及装置、计算机设备及存储介质 |
| CN111905111B (zh) * | 2020-09-16 | 2023-03-31 | 地奥集团成都药业股份有限公司 | 一种评价复方谷氨酰胺组方对腹泻型肠易激综合征疗效的方法 |
| US20220208375A1 (en) * | 2020-12-29 | 2022-06-30 | Kpn Innovations, Llc. | System and method for generating a digestive disease functional program |
| CN115328117B (zh) * | 2022-07-15 | 2023-07-14 | 大理大学 | 基于强化学习的蛋白质动态配体通道最优路径分析方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999057120A1 (en) * | 1998-05-04 | 1999-11-11 | Neotherapeutics, Inc. | Novel serotonin-like 9-substituted hypoxanthine and methods of use |
| EP1315837A2 (en) * | 2000-09-06 | 2003-06-04 | Glaxo Group Limited | 5-hydroxytryptamine receptor gene polymorphisms and response to treatment |
| US20080085524A1 (en) * | 2006-08-15 | 2008-04-10 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
| EP2778685B1 (en) * | 2009-06-25 | 2017-04-26 | Nestec S.A. | Methods for diagnosing irritable bowel syndrome |
-
2010
- 2010-10-29 EP EP10827556.1A patent/EP2494074A4/en not_active Withdrawn
- 2010-10-29 CA CA2778539A patent/CA2778539A1/en not_active Abandoned
- 2010-10-29 JP JP2012537132A patent/JP2013509593A/ja not_active Withdrawn
- 2010-10-29 MX MX2012005015A patent/MX2012005015A/es unknown
- 2010-10-29 CN CN2010800605536A patent/CN102712956A/zh active Pending
- 2010-10-29 WO PCT/US2010/054810 patent/WO2011053831A1/en not_active Ceased
- 2010-10-29 RU RU2012122180/15A patent/RU2012122180A/ru unknown
- 2010-10-29 PH PH1/2012/500850A patent/PH12012500850A1/en unknown
- 2010-10-29 KR KR1020127013948A patent/KR20120101038A/ko not_active Withdrawn
- 2010-10-29 BR BR112012010108A patent/BR112012010108A2/pt not_active IP Right Cessation
- 2010-10-29 AU AU2010313292A patent/AU2010313292A1/en not_active Abandoned
-
2012
- 2012-04-06 US US13/441,658 patent/US20120315630A1/en not_active Abandoned
- 2012-04-19 IL IL219317A patent/IL219317A0/en unknown
- 2012-05-22 ZA ZA2012/03718A patent/ZA201203718B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20120315630A1 (en) | 2012-12-13 |
| ZA201203718B (en) | 2014-11-26 |
| MX2012005015A (es) | 2012-06-12 |
| IL219317A0 (en) | 2012-06-28 |
| PH12012500850A1 (en) | 2013-01-07 |
| CN102712956A (zh) | 2012-10-03 |
| JP2013509593A (ja) | 2013-03-14 |
| CA2778539A1 (en) | 2011-05-05 |
| AU2010313292A1 (en) | 2012-06-07 |
| EP2494074A4 (en) | 2013-06-12 |
| KR20120101038A (ko) | 2012-09-12 |
| BR112012010108A2 (pt) | 2016-05-31 |
| WO2011053831A1 (en) | 2011-05-05 |
| EP2494074A1 (en) | 2012-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012122180A (ru) | Способы диагностики синдрома раздраженного кишечника | |
| US11241395B2 (en) | Use of procalcitonin (PCT) in risk stratification and prognosis of patients with a primary, non-infectious disease | |
| JP2013509593A5 (enExample) | ||
| EP3482200B1 (en) | Protein signatures for distinguishing between bacterial and viral infections | |
| JP2019194600A (ja) | 過敏性腸症候群を診断するための経路特異的マーカー | |
| ES2536761T3 (es) | Detección de infecciones bacterianas en individuos que padecen disnea | |
| JP2013511988A (ja) | 過敏性腸症候群診断用の新規なゲノムバイオマーカー | |
| JP2007513337A (ja) | アルツハイマー病の診断方法、層化方法およびモニタリング方法 | |
| CN108700596A (zh) | 用于心血管疾病和事件的诊断和预后方法 | |
| US20070134738A1 (en) | Methods for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses | |
| JPWO2008120684A1 (ja) | 急性中枢神経障害の予後判定方法 | |
| EP2376919A1 (en) | Combined natriuretic peptide assays | |
| CN114980801A (zh) | 阿尔茨海默氏病的评价和治疗方法及其应用 | |
| US9046532B2 (en) | Risk assessment for antibiotics treatment in patients suffering from primary non-infectious disease by determining the level of procalcitonin | |
| KR20100127210A (ko) | 비특이적 질환용 일반 마커로서의 ｙｋｌ-40 | |
| JP2008507686A (ja) | リウマチ様関節炎（ｒａ）のためのバイオマーカー | |
| BE1021759B1 (fr) | Marqueurs pour la consolidation alteree des fractures osseuses | |
| TWI606060B (zh) | 用於檢測神經性乙醯膽鹼受器阿爾法七次單位抗體之多肽分子 | |
| Schaler et al. | Impact of COVID-19 vaccination on seminal and systemic inflammation in men | |
| Ulugbekovich | THE ROLE OF LABORATORY AND INSTRUMENTAL METHODS IN THE DIAGNOSIS AND ASSESSMENT OF THE CLINICAL COURSE OF TUBERCULOSIS | |
| Rey Amunategui et al. | Comparison of symmetric dimethylarginine, plasma aldosterone concentration, renin activity and systolic blood pressure between diabetic and non-diabetic cats with hypersomatotropism | |
| Arndt | Development of multiple-micronutrient and environmental enteric dysfunction assessment tool (MEEDAT) | |
| RU2476885C1 (ru) | Способ прогнозирования длительности проведения искусственной вентиляции легких у больных с тяжелой формой гийена-барре | |
| CN121231781A (zh) | Creld2作为早期生物标志物在诊断、预测或预后脓毒症中的用途 | |
| Wong et al. | Predictive factors in the development of post-infectious irritable bowel syndrome |